Literature DB >> 23943874

Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.

Susanne Köthe1, Jörg P Müller, Sylvia-Annette Böhmer, Todor Tschongov, Melanie Fricke, Sina Koch, Christian Thiede, Robert P Requardt, Ignacio Rubio, Frank D Böhmer.   

Abstract

FMS-like tyrosine kinase 3 with internal tandem duplication (FLT3 ITD) is an important oncoprotein in acute myeloid leukemia (AML). Owing to its constitutive kinase activity FLT3 ITD partially accumulates at endomembranes, a feature shared with other disease-associated, mutated receptor tyrosine kinases. Because Ras proteins also transit through endomembranes we have investigated the possible existence of an intracellular FLT3-ITD/Ras signaling pathway by comparing Ras signaling of FLT3 ITD with that of wild-type FLT3. Ligand stimulation activated both K- and N-Ras in cells expressing wild-type FLT3. Live-cell Ras-GTP imaging revealed ligand-induced Ras activation at the plasma membrane (PM). FLT3-ITD-dependent constitutive activation of K-Ras and N-Ras was also observed primarily at the PM, supporting the view that the PM-resident pool of FLT3 ITD engaged the Ras/Erk pathway in AML cells. Accordingly, specific interference with FLT3-ITD/Ras signaling at the PM using PM-restricted dominant negative K-RasS17N potently inhibited cell proliferation and promoted apoptosis. In conclusion, Ras signaling is crucial for FLT3-ITD-dependent cell transformation and FLT3 ITD addresses PM-bound Ras despite its pronounced mislocalization to endomembranes.

Entities:  

Keywords:  AML; Endomembrane; FLT3; FLT3 ITD; Leukemia; Localization; Oncogenic RTK; Plasma membrane; Ras

Mesh:

Substances:

Year:  2013        PMID: 23943874     DOI: 10.1242/jcs.131789

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  11 in total

1.  Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains.

Authors:  Martin Augsten; Anika Böttcher; Rainer Spanbroek; Ignacio Rubio; Karlheinz Friedrich
Journal:  Cell Commun Signal       Date:  2014-01-02       Impact factor: 5.712

2.  Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML.

Authors:  Jennifer N Moloney; Ashok Kumar Jayavelu; Joanna Stanicka; Sarah L Roche; Rebecca L O'Brien; Sebastian Scholl; Frank-D Böhmer; Thomas G Cotter
Journal:  Oncotarget       Date:  2017-11-01

3.  Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers.

Authors:  Swapnil C Kamble; Arijit Sen; Rahul D Dhake; Aparna N Joshi; Divya Midha; Sharmila A Bapat
Journal:  J Clin Med       Date:  2019-03-08       Impact factor: 4.241

4.  N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.

Authors:  Yuuki Obata; Yasushi Hara; Isamu Shiina; Takatsugu Murata; Yasutaka Tasaki; Kyohei Suzuki; Keiichi Ito; Shou Tsugawa; Kouhei Yamawaki; Tsuyoshi Takahashi; Koji Okamoto; Toshirou Nishida; Ryo Abe
Journal:  Cell Commun Signal       Date:  2019-09-04       Impact factor: 5.712

Review 5.  Uncoupling Traditional Functionalities of Metastasis: The Parting of Ways with Real-Time Assays.

Authors:  Sagar S Varankar; Sharmila A Bapat
Journal:  J Clin Med       Date:  2019-06-28       Impact factor: 4.241

Review 6.  Mutations of FLT3 receptor affect its surface glycosylation, intracellular localization, and downstream signaling.

Authors:  Shinichiro Takahashi
Journal:  Leuk Res Rep       Date:  2019-11-27

7.  FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.

Authors:  Kouhei Yamawaki; Isamu Shiina; Takatsugu Murata; Satoru Tateyama; Yutarou Maekawa; Mariko Niwa; Motoyuki Shimonaka; Koji Okamoto; Toshihiro Suzuki; Toshirou Nishida; Ryo Abe; Yuuki Obata
Journal:  Sci Rep       Date:  2021-11-22       Impact factor: 4.379

8.  Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.

Authors:  Alissa Marhäll; Florian Heidel; Thomas Fischer; Lars Rönnstrand
Journal:  Ann Hematol       Date:  2018-01-25       Impact factor: 3.673

9.  Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.

Authors:  Xiaomeng Huang; Sebastian Schwind; Ramasamy Santhanam; Ann-Kathrin Eisfeld; Chi-Ling Chiang; Malori Lankenau; Bo Yu; Pia Hoellerbauer; Yan Jin; Somayeh S Tarighat; Jihane Khalife; Alison Walker; Danilo Perrotti; Clara D Bloomfield; Hongyan Wang; Robert J Lee; Ly James Lee; Guido Marcucci
Journal:  Oncotarget       Date:  2016-09-13

10.  Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics.

Authors:  Fabienne Kellner; Andreas Keil; Katrin Schindler; Todor Tschongov; Kerstin Hünninger; Hannah Loercher; Peter Rhein; Sylvia-Annette Böhmer; Frank-D Böhmer; Jörg P Müller
Journal:  J Cell Mol Med       Date:  2020-03-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.